First Follow-Up of Cardiac Amyloidosis Treated by Tafamidis, Evaluated by Absolute Quantification in Bone Scintigraphy
Dimitri Bellèvre, Alban Bailliez, Sylvestre Maréchaux, Alain Manrique, Frédéric Mouquet
Abstract
Assessment of absolute myocardial hydroxydimethylene diphosphonate–technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography–computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. This imaging technique should be helpful in monitoring therapy and evaluating prognosis. (Level of Difficulty: Intermediate.)
Topics & Concepts
Cardiac amyloidosisMedicineNuclear medicineBone scintigraphyScintigraphyCadmium zinc tellurideRadiologyRadionuclide imagingTransthyretinInternal medicineEngineeringElectrical engineeringDetectorAmyloidosis: Diagnosis, Treatment, OutcomesMedical Imaging and Pathology StudiesSarcoidosis and Beryllium Toxicity Research